Showing 7021-7030 of 8887 results for "".
- Study Links Psoriasis Gene Regulation to Spatial Genome Changeshttps://practicaldermatology.com/news/study-links-psoriasis-gene-regulation-to-spatial-genome-changes/2474007/Results from a new study in the Journal of Investigative Dermatology showed how changes in the 3D chromatin architecture of CD4+ T cells contribute to immune dysregulation in psoriasis. "In this study, the 3D genomic
- Study: Dermabrasion Trials Rarely Report Race or Skin Typehttps://practicaldermatology.com/news/study-dermabrasion-trials-rarely-report-race-or-skin-type/2474005/Most clinical trials studying dermabrasion have failed to report racial or skin-type demographics, according to a new systematic review. "Clinical trials that are racially homogenous or do not report race limit the generalizab
- Bimekizumab Trials 'Raise the Bar' for HS, Dr. Vivian Shi Sayshttps://practicaldermatology.com/news/Bimekizumab-Trials-Raise-Bar-HS-Dr-Vivian-Shi-Says/2473933/More than half of hidradenitis suppurativa (HS) patients treated with bimekizumab (BIMZELX, UCB) had no draining tunnels (DTs) at 2 years, and 63.6% reported no or mild skin pain, compared to 10.0% at baseline, according to new data presented at the 2025 American Academy of Dermatology (AAD) Annu
- Obesity and Epidermal Innate Immunity Linked to Resistance to Biologic Therapy in Psoriasishttps://practicaldermatology.com/news/obesity-and-epidermal-innate-immunity-linked-to-resistance-to-biologic-therapy-in-psoriasis/2473927/Patients with severe plaque psoriasis who are overweight are more likely to experience resistance to biologic therapies, according to new findings The study researchers designed and conducted a cross-sectional study at Gachon
- Bimekizumab Results Continue to Impress for PsO, HShttps://practicaldermatology.com/news/Bimekizumab-Results-Continue-Impress-PsO-HS/2473847/Dual inhibition with bimekizumab (BIMZELX, UCB) in adults with moderate-to-severe plaque psoriasis demonstrated high efficacy and sustained clinical benefits, according to new long-term data from phase 3 trials and their open-label extensions. Among patients with psoriasis only at baseline
- Dr. Raj Chovatiya: Lebrikizumab Long-Term Data Makes 'Night and Day' Differencehttps://practicaldermatology.com/news/Dr-Raj-Chovatiya-Lebrikizumab-Long-Term-Data-Makes-Night-Day-Difference/2471865/New long-term results presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, showed complete skin clearance (EASI-100 or IGA 0) at 3 years in patients with moderate-to-severe atopic dermatitis taking lebrikizumab (EBGLYSS™, Eli Lilly and Company) in the AD
- Biologics Linked to Lower Infection Risk in Older Psoriatic Patients: Studyhttps://practicaldermatology.com/news/biologics-linked-to-lower-infection-risk-in-older-psoriatic-patients-study/2471809/Biologics targeting interleukin (IL)-12, IL-23, and IL-17 were associated with lower rates of serious infection in older adults with psoriatic disease, according to a cohort study using Ontario health data. The study, publishe
- Emrosi Officially Launched for Treatment of Inflammatory Rosaceahttps://practicaldermatology.com/news/emrosi-officially-launched-for-treatment-of-inflammatory-rosacea/2471775/Journey Medical has announced the launch and initial prescriptions for Emrosi for the treatment of inflammatory lesions of rosacea in adults. According to a press release from the manufacturer, the minocycline hydrochloride modi
- Colloidal Oatmeal Moisturizer in Managing Skin Microbiota: Studyhttps://practicaldermatology.com/news/colloidal-oatmeal-moisturizer-in-managing-skin-microbiota-study/2471650/A new in vitro study suggests a moisturizer containing colloidal oatmeal, patented filaggrin technology, niacinamide, and tocopheryl acetate selectively inhibits the growth and adhesion of Staphylococcus aureus (S. aureus) while promoting Staphylococcus epidermidis
- PN Therapeutic Pipeline Continues to Show Promisehttps://practicaldermatology.com/news/PN-Therapeutic-Pipeline-Continues-Show-Promise/2471649/The US Food and Drug Administration (FDA) approval last year of nemolizumab for the treatment of adults with prurigo nodularis (PN) was likely only the beginning of a dramatically changing therapeutic landscape for that condition, Sonja Stander, MD, IFAAD, said at the 2025 American Academy of Der